Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

MLA

Stephen R. Lane, et al. “Randomized Phase II Study of Lapatinib plus Capecitabine or Lapatinib plus Topotecan for Patients with HER2-Positive Breast Cancer Brain Metastases.” Journal of Neuro-Oncology, vol. 105, no. 3, Mar. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....56906bc4e74c471fd2b99576801828f4&authtype=sso&custid=ns315887.

APA

Stephen R. Lane, Denise Zembryki, Wolfgang Eierman, Nan Lin, Richard Greil, Stephen D. Rubin, Mario Campone, Klaudia Steplewski, Bella Kaufman, & Eric P. Winer. (2011). Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. Journal of Neuro-Oncology, 105(3).

Chicago

Stephen R. Lane, Denise Zembryki, Wolfgang Eierman, Nan Lin, Richard Greil, Stephen D. Rubin, Mario Campone, Klaudia Steplewski, Bella Kaufman, and Eric P. Winer. 2011. “Randomized Phase II Study of Lapatinib plus Capecitabine or Lapatinib plus Topotecan for Patients with HER2-Positive Breast Cancer Brain Metastases.” Journal of Neuro-Oncology 105 (3). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....56906bc4e74c471fd2b99576801828f4&authtype=sso&custid=ns315887.